Compare CANF & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | HLN |
|---|---|---|
| Founded | 1994 | 2022 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 43.7B |
| IPO Year | 2011 | N/A |
| Metric | CANF | HLN |
|---|---|---|
| Price | $3.22 | $10.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | 609.7K | ★ 8.3M |
| Earning Date | 03-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $461.72 | $7.04 |
| Revenue Next Year | $290,391.28 | $4.58 |
| P/E Ratio | ★ N/A | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $8.71 |
| 52 Week High | $10.40 | $11.42 |
| Indicator | CANF | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 40.69 |
| Support Level | $0.60 | $9.98 |
| Resistance Level | $4.74 | $10.31 |
| Average True Range (ATR) | 0.64 | 0.15 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 0.90 | 14.30 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.